<DOC>
	<DOCNO>NCT01801111</DOCNO>
	<brief_summary>This open-label , non-randomized , multicenter phase I/II study evaluate safety efficacy RO5424802 patient non-small cell lung cancer ALK mutation fail crizotinib treatment . In Part 1 , cohort patient receive escalate dos RO5424802 orally twice daily . In Part 2 , patient receive recommend phase II dose RO5424802 determine Part 1 . Treatment continue Part 1 Part 2 dose disease progression . In Part 3 , follow disease progression , patient without EGFR mutation offer continued treatment RO5424802 , patient EGFR mutation offer combination RO5424802 Tarceva ( erlotinib ) .</brief_summary>
	<brief_title>A Study RO5424802 Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation Failed Crizotinib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Locally advance metastatic nonsmall cell lung cancer ( stage IIIB IV AJCC 7th ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Documented ALK rearrangement base FDA approve test Prior treatment crizotinib progression accord RECIST v1.1 criterion last dose crizotinib within 60 day enrolment ; patient either chemotherapyna√Øve receive least one line platinumbased chemotherapy Adequate hematologic , hepatic renal function Patients brain leptomeningeal metastasis allow study lesion asymptomatic without neurological sign clinically stable least 2 week Measurable disease accord RECIST v1.1 prior administration study drug Receipt ALK inhibitor addition crizotinib Receipt prior cytotoxic chemotherapy ALKpositive NSCLC within 4 week prior Day 1 . Patients receive crizotinib tyrosine kinase inhibitor need minimum 2week washout period first dose Active uncontrolled infectious disease require treatment NCI CTCAE ( version 4.03 ) Grade 3 high toxicity due prior therapy show improvement consider interfere current study medication History organ transplant Coadministration anticancer therapy administer study Baseline QTc &gt; 470 m baseline symptomatic bradycardia &lt; 45 beat per minute Pregnant breastfeeding woman Known HIV positivity AIDSrelated illness History significant drugrelated allergy ( anaphylaxis ) Any clinically significant concomitant disease condition could interfere , treatment might interfere , conduct study , absorption oral medication , would , opinion principal investigator , pose unacceptable risk subject study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>